Perfluorinated Compounds (PFAS) vs Recombinant Bovine Growth Hormone: which is worse?

What is Perfluorinated Compounds (PFAS)?

Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemicals characterized by extremely strong carbon-fluorine bonds. They are used in food packaging (grease-resistant coatings), non-stick cookware (PTFE/Teflon), food processing equipment, firefighting foam, and many industrial applications. The 'forever chemicals' moniker reflects their extreme environmental persistence.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Perfluorinated Compounds (PFAS): PFAS are among the most extensively studied and harmful groups of synthetic chemicals in the modern environment. Their unique carbon-fluorine bond stability means they do not break down in the environment or in human body tissues — contributing to bioaccumulation over a lifetime. Health effects documented in human epidemiological studies include: - Cancer: PFOA (perfluorooctanoic acid) and PFOS (perfluorooctanesulfonic acid) have been associated with kidney cancer, testicular cancer, thyroid cancer, bladder cancer, and non-Hodgkin lymphoma in occupationally exposed workers and community members with contaminated drinking water. IARC classified PFOA as Group 1 (human carcinogen) in 2023 and PFOS as Group 2B. - Endocrine disruption: PFAS disrupt thyroid hormone signaling and sex hormone balance. Multiple studies find associations between PFAS exposure and hypothyroidism, early puberty in girls, and reduced sperm quality. - Immune suppression: studies have found that PFAS exposure is associated with reduced vaccine response in children and adults, suggesting PFAS may impair immune function. - Developmental effects: prenatal PFAS exposure has been associated with lower birth weight, developmental delays, and reduced immune response in infants. - Cholesterol: PFAS exposure consistently raises LDL cholesterol levels, increasing cardiovascular disease risk. The 2023 EPA MCLG (maximum contaminant level goal) for PFOA and PFOS is zero — reflecting the agency's conclusion that there is no safe level. The EPA set enforceable MCLs in drinking water in 2024. The DuPont/3M PFOA/PFOS contamination of drinking water in communities near Teflon manufacturing facilities led to a $671 million settlement (DuPont/Chemours, 2017) and $10.3 billion 3M settlement (2023) — among the largest environmental contamination settlements in history.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.